The Food and Drug Administration (FDA) has accepted for review a New Drug Application for ET-105, a new liquid formulation of lamotrigine.

The ET-105 formula is being developed specifically for patients with dysphagia and pediatric patients requiring dosing at levels below the currently available tablet strengths. According to the Company, ET-105 dosing delivery system will allow for measurements down to 1mg.

Related Articles

“Our team looks forward to working with Aucta and the FDA over the coming months as we prepare for a potential commercial launch in the first half of 2020,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals. 

The Company is seeking approval of ET-105 as an adjunct therapy for partial seizures, primary generalized tonic-clonic seizures, and generalized seizures of Lennox-Gastaut syndrome in patients 2 years of age and older.

Continue Reading

A Prescription Drug User Fee Act (PDUFA) date of March 17, 2020 has been set for this application.

For more information visit

This article originally appeared on MPR